Breast — Screening in BRCA1 Mutation Carriers
A 32-year-old woman attends clinic asking about breast cancer screening. She has no breast lump or nipple discharge, and her breast examination is normal. Her mother was diagnosed with breast cancer at 45 years of age, and the patient recently had genetic testing that showed a pathogenic BRCA1 mutation. She takes a combined oral contraceptive pill. Which screening plan is most appropriate?
- A.Breast ultrasound every 6 months, starting now
- B.Annual breast MRI with mammography, starting nowCorrect
- C.Annual clinical breast examination alone until age 40
- D.Annual mammography alone, starting at 35 years of age
Explanation
A woman with a pathogenic BRCA1 mutation has a lifetime breast cancer risk of roughly 60 to 70 percent and tends to develop cancer young, so she qualifies for high-risk surveillance regardless of any calculated model score. NCCN advises annual contrast-enhanced breast MRI from age 25, with annual mammography added from age 30, plus clinical breast examination every 6 to 12 months. At 32 she should therefore start both annual MRI and mammography now. MRI is the core of the plan because BRCA1 tumours are often fast-growing, triple-negative and mammographically subtle in dense young breasts, and its sensitivity is far higher than mammography alone. Waiting until 35 for mammography leaves her without MRI, the most sensitive tool, during her years of highest incident risk. Ultrasound is only a fallback when MRI cannot be done, and clinical examination alone misses small cancers. Her combined oral contraceptive does not change the screening schedule, though contraception choices and risk-reducing salpingo-oophorectomy by 35 to 40 years should be discussed. The point most often missed is that a known carrier skips risk modelling entirely.
Why each option
- A.
- Ultrasound has lower sensitivity than MRI and is reserved for carriers who cannot undergo MRI, not used as first-line surveillance.
- B.
- Correct. BRCA1 carriers aged 30 or older need annual breast MRI plus annual mammography, so surveillance should begin immediately at 32.
- C.
- Clinical breast examination is a supplement every 6 to 12 months and cannot replace imaging in a known BRCA1 carrier.
- D.
- Delaying to 35 and omitting MRI leaves her without the most sensitive test during years when BRCA1 cancers commonly arise.
Reference: NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment — Breast, Ovarian, Pancreatic and Prostate (v.2.2025); ACR Breast Cancer Screening Recommendations for Higher-Than-Average Risk Women (2023)
This is one of 3,306 questions in the MedBoardSA SMLE bank, with timed test mode, tutor mode, and progress tracking by topic.
Practise the full bank